PolyPid Ltd. (PYPD)
NASDAQ: PYPD · Real-Time Price · USD
5.22
-0.14 (-2.61%)
At close: Sep 25, 2026, 4:00 PM EDT
5.32
+0.10 (1.92%)
After-hours: Sep 25, 2026, 7:30 PM EDT
PolyPid Employees
As of December 31, 2025, PolyPid had 75 total employees, including 69 full-time and 6 part-time employees. The number of employees increased by 14 or 22.95% compared to the previous year.
Employees
75
Change (1Y)
14
Growth (1Y)
22.95%
Revenue / Employee
n/a
Profits / Employee
-$420,013
Market Cap
106.03M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 75 | 14 | 22.95% | 69 | 6 |
| Dec 31, 2024 | 61 | -1 | -1.61% | 57 | 4 |
| Dec 31, 2023 | 62 | 2 | 3.33% | 59 | 3 |
| Dec 31, 2022 | 60 | -19 | -24.05% | 57 | 3 |
| Dec 31, 2021 | 79 | 10 | 14.49% | 75 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| Cibus | 118 |
| Rani Therapeutics Holdings | 71 |
| Vivani Medical | 42 |
| Milestone Pharmaceuticals | 38 |
| Aardvark Therapeutics | 28 |
| Genelux | 26 |
| Black Diamond Therapeutics | 21 |
PYPD News
- 11 days ago - PolyPid Announces Participation in Upcoming Fall Investor Conferences - GlobeNewsWire
- 5 weeks ago - PolyPid reports Q2 EPS (35c), consensus (38c) - TheFly
- 6 weeks ago - PolyPid Earnings Call Transcript: Q2 2026 - Transcripts
- 6 weeks ago - PolyPid Earnings release: Q2 2026 - Filings
- 6 weeks ago - PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results - GlobeNewsWire
- 1 month ago - PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026 - GlobeNewsWire
- 1 month ago - PolyPid NDA acceptance ‘meets or exceeds’ expectations, says Roth Capital - TheFly
- 1 month ago - PolyPid announces FDA acceptance of, priority review for D-PLEX100 - TheFly